Memphasys Ltd (AU:MEM) has released an update.
Memphasys Ltd, an Australian reproductive biotechnology firm, has secured a $500,000 short-term loan from Keystonegroup Investments to support its commercialization activities, including the completion of the Felix™ System clinical trial and advancing equine fertility studies. These initiatives are poised to strengthen the company’s position in the reproductive technology market, as they work towards key milestones and expand into new markets.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
